Facebook-f X-twitter Linkedin-in Instagram Podcast

Thoracic Oncology Group of Australasia

Clinical Trials

Get the latest news, treatments, ASM highlights and topics in lung cancer and mesothelioma from The Thoracic Oncology Group of Australasia (TOGA).

Post Category Filter Radio Buttons
Medical oncologist discussing KRAS G12C genomic test results with a patient, with illustrations of lungs, DNA and targeted therapy representing precision medicine for lung cancer.
What is KRAS G12C Lung Cancer? Understanding Targeted Treatment and Clinical Trials
Learn what a KRAS G12C mutation means, how targeted therapies work, and how Australian clinical trials are testing new lung cancer treatments.
PHARAOH-A
The PHARAOH-A trial will evaluate savolitinib plus osimertinib in MET-positive amplified or overexpressed EGFR-mutated lung cancer after progression on prior TKI and chemotherapy.
A flowchart detailing the ASPiRATION 2-Liquid study design. The study is an observational cohort of 500 adults with metastatic NSCLC, who have disease progression on targeted therapy and an ECOG performance status of 0-2. After consenting to screening, participants undergo both liquid biopsy and, if a biopsy was performed, tissue NGS.
ASPiRATION 2L: Liquid Biopsy Clinical Trial for Advanced Lung Cancer Patients Across Australia
Everything you need to know about the Australia-wide trial using liquid biopsy to guide treatment after targeted therapy progression in advanced lung cancer
Diagram summarising the DEFIANT phase 2 clinical trial evaluating datopotamab deruxtecan (Dato-DXd) in metastatic EGFR exon 20 insertion non-small cell lung cancer.
DEFIANT: A new clinical trial for EGFR exon20 insertion lung cancer
The DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in EGFR exon 20 insertion NSCLC after targeted therapy and chemotherapy.
Mobilising teletrials
Teletrials, also known as digi trials, are when a clinician at a primary site uses telehealth (videoconference or telephone calls) to enrol, consent, treat and/or
Clinical Trial Design Series: Glossary of Clinical Trial Terms and Acronyms in Cancer Research
Understanding the language helps patients, families and clinicians stay informed, confident and part of the conversation.
Clinical Trial Design Series: Turning a Concept into a Clinical Trial
Learn how to turn your endorsed research concept into a clinical trial; from sponsor selection to budgeting, data, safety and protocol design.
Clinical trial design concept showing hypothesis to endpoint planning and sample size calculation on a chalkboard with a glowing lightbulb representing a research idea.
Clinical Trial Design Series: Getting Started with Investigator-Initiated Trials
Learn how to design an investigator-initiated clinical trial, from refining your research idea to securing TOGA endorsement and funding.
Lung Cancer in 2025: Key Advances in Screening, Diagnosis and Treatment in Australia
Discover how 2025 transformed lung cancer care in Australia. Explore the impact of national screening, modern diagnostics, and new PBS treatment approvals.
DYNAMALK Clinical Trial: Dynamic Molecular Profiling in ALK-Positive Lung Cancer
DYNAMALK is a significant clinical trial investigating the potential of comprehensive genomic profiling to revolutionise the treatment of ALK+ Non-Small Cell Lung Cancer (NSCLC)
OCEANIC clinical trial schema
OCEANiC clinical trial: Optimising Adjuvant Therapy in Early-Stage EGFR-Mutant Lung Cancer
OCEANiC will determine if patients with resected stage II to IIIA EGFR mutant NSCLC require intensification of osimertinib monotherapy with chemotherapy.
SHERLOCK Clinical Trial: Promising First-Line Results for KRAS G12C-Mutated Lung Cancer
Latest results from the SHERLOCK clinical trial show promising first-line outcomes for patients with KRAS G12C-mutated lung cancer, combining sotorasib with chemotherapy and bevacizumab.
Headshot of Prof Paul Keall with title 'Prof Paul Keall leading VITal trial'
Innovative Imaging Clinical Trial Aims to Reduce Lung Toxicity in Radiation Therapy
A new Australian trial could improve outcomes for people with lung cancer by reducing radiation-related lung damage.
Headshot of Shankar Siva on light blue background
Prof Siva receives $1.5M funding for PRIME-Lung Clinical Trial
Prof Shankar Siva has received a $1.5 million MRFF grant for phase III trial PRIME-Lung
Lung and medicine AI image
ADOPT-Lung Clinical Trial Recruitment Now Open
TOGA is excited to be part of the European Thoracic Oncology Platform (ETOP) ADOPT-Lung clinical trial, with recruitment expected to open towards the end of
The Cornerstone of Progress: Why Clinical Trials Are Vital in Lung Cancer
Clinical trials are the bedrock of this progress, driving the development of new and more effective treatments that can significantly improve the lives of individuals
lung image with medical symbols surrounding
ASPiRATION
An observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients
Beyond the Myths: Unveiling the Truth About Clinical Trials for Lung Cancer
Have you been diagnosed with lung cancer and are overwhelmed by treatment options?
Five Things to Consider When Participating in a Clinical Trial
Five Things to Consider When Participating in a Clinical Trial
Facing a diagnosis can be a daunting journey, rife with uncertainty and difficult decisions. Among these decisions is the choice of whether to participate in
TOGA Researcher Clinical Trials
Three Reasons You Should Participate in Clinical Trials
Three compelling reasons why becoming a participant in cancer clinical trials is not only a noble endeavor but also a decision that can hold profound
Join our community – stay up to date with the latest research, TOGA news and events

The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Contact

PO Box 1103
Thornbury VIC 3071
Ph: +61 3 9087 3550
ABN: 47 641 984 198

Facebook-f X-twitter Linkedin-in Instagram Podcast
TOGA
Quicklinks
TOGA is an ACNC Registered Charity

Thoracic Oncology Group of Australasia is registered with the Australian Taxation Office as an Income Tax Exempt Charitable Entity. Donations $2 and over are tax deductible.

Copyright © 2026 TOGA – Thoracic Oncology Group Australasia. No part of this site may be reproduced without our written permission.